Valuation: Quest PharmaTech Inc.

Market Cap 3.38M 2.42M 2.17M 2M 1.81M 230M 3.44M 23.85M 9.51M 121M 9.08M 8.89M 382M P/E 2025
-3.29x
P/E 2026 1.18x
Enterprise Value 4.37M 3.12M 2.8M 2.58M 2.34M 297M 4.44M 30.8M 12.29M 156M 11.72M 11.47M 493M EV / Sales 2025
-
EV / Sales 2026 -
Free-Float
83.12%
Yield 2025 *
-
Yield 2026 -
Current month-20.00%
1 month-20.00%
3 months-20.00%
6 months-33.33%
Current year-42.86%
1 week 0.02
Extreme 0.02
0.02
1 month 0.02
Extreme 0.02
0.02
Current year 0.02
Extreme 0.02
0.04
1 year 0.02
Extreme 0.02
0.05
3 years 0.02
Extreme 0.015
0.07
5 years 0.02
Extreme 0.015
0.16
10 years 0.02
Extreme 0.015
0.32
Manager TitleAgeSince
Chief Executive Officer - 16/06/2004
Director of Finance/CFO - 31/12/2004
Director TitleAgeSince
Director/Board Member - 16/06/2004
Chairman - 04/07/2021
Director/Board Member - 04/07/2021
Date Insider Type Main position Quantity % Market Cap. Importance
12/12/25 OtherCompany 0 0% -
21/10/25 Other

Chief Executive Officer

1,000,000 0.5913%
21/10/25 Other

Chief Executive Officer

300,000 0.1774%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-50.00%-69.23% 2.41M
+0.34%-3.03%+37.45%+61.06% 64.14B
+0.98%+2.26%+12.91%+82.98% 55.53B
+1.75%+2.76%+12.38%+103.69% 53.03B
-1.43%-0.57%+26.10%+52.86% 45.99B
-0.48%-3.86%+17.27%+117.99% 42.45B
+0.82%-2.06%+227.09%+922.41% 40.45B
-0.26%-4.20%+10.86%+45.18% 32.25B
-2.07%+44.58%+102.84%+88.74% 34.47B
-2.72%-8.79%+22.58%-5.63% 24.23B
Average -0.33%+3.44%+41.95%+140.00% 39.25B
Weighted average by Cap. -0.11%+3.13%+49.26%+160.88%

Financials

2025 2026
Net sales - -
Net income -1.8M -1.29M -1.15M -1.06M -963K -123M -1.83M -12.7M -5.07M -64.19M -4.83M -4.73M -203M 5M 3.57M 3.2M 2.95M 2.67M 340M 5.08M 35.24M 14.06M 178M 13.42M 13.13M 564M
Net Debt 795K 568K 509K 470K 425K 54.14M 808K 5.6M 2.24M 28.33M 2.13M 2.09M 89.73M 986K 705K 631K 582K 527K 67.12M 1M 6.95M 2.77M 35.13M 2.65M 2.59M 111M
Projected Income Statement - Annual - Quest PharmaTech Inc.
Logo Quest PharmaTech Inc.
Quest PharmaTech Inc. is a Canada-based biopharmaceutical company. The Company is developing products to improve the quality of life. The Company is also developing a proprietary MAb AR 9.6 targeting truncated MUC16 as theranostic agents for cancer. The Company has a 42.5% ownership interest in OncoQuest Inc. (OncoQuest), a Canadian biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest’s technology platform included a panel of tumor antigen-specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. The Company also has a 23% ownership interest in OncoVent Co., Ltd. (OncoVent), which is developing antibody-based immunotherapeutic products for cancer for the Greater China territory.
Employees
-
Date Price Change Volume
29/10/26 CA$0.0200 0.00% 2,000